Where is HCmed located?

HCmed is headquartered in Taipei, Taiwan.

Who is the current CEO of HCmed?

Jason Cheng of HCmed. They have also founded 1 company.

How many employees does HCmed have?

As of Aug 31, 2026, the latest employee count at HCmed is 35.

Where does HCmed rank among its competitors?

HCmed ranks 40th amongst 80 active competitors, of which 21 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Nebu~Flow, which secured $2.69M in Jun, 2026.

Who are the top competitors of HCmed?

HCmed's top competitors include MannKind Corp, Impel NeuroPharma and NeOnc Technologies. Among them, Nebu~Flow secured the most recent funding round in June, 2026.

HCmed - 2026 Company Profile, Team & Competitors

Company Details

Developer of inhalation device to treat people suffering from respiratory diseases. The products include deepro which is a standard mesh nebulizer, Pulmogine is a customization platform for drug-device combination, and AdheResp is a breath-actuated drug-device combination platform. These devices are integrated with an app that records and enhances the treatment.

Website: hcmed-inno.com
Email ID: *****@hcmed-inno.com
Phone Number: +886 **********

Key Metrics

Founded Year

2014

Location

Taipei, Taiwan

Stage

Public

Ranked

40^th among 80 active competitors

Employee Count

35 as on Aug 31, 2026

Similar Companies

MannKind Corp & 90 more

Exit Details

Public

View HCmed's full profile

HCmed got listed on Jun 25, 2024.

Click here to take a look at HCmed's IPO in detail

HCmed has not raised any funding rounds yet.

The founders of HCmed is Jason Cheng. Jason Cheng is the CEO of HCmed.

Here are the details of HCmed's key team members:

Jason Cheng: Founder & CEO of HCmed.
Contact Info: 1 email address

View details of HCmed's Founder profiles and Board Members

HCmed's employee count trend

HCmed has 35 employees as of Aug 26. Here is HCmed's employee count trend over the years:

Uncover HCmed's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of HCmed include MannKind Corp, Impel NeuroPharma and NeOnc Technologies. Here is the list of Top 10 competitors of HCmed, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Ignite 500 & 1 others	70/100
2nd	Impel NeuroPharma 2008, Seattle (United States), Public	Developer of an intranasal drug delivery technology for CNS diseases	$120M	VenBio, Norwest & 7 others	63/100
3rd	NeOnc Technologies 2008, Los Angeles (United States), Public	Developer of drug delivery methods for pharma-based therapeutics	$18.7M	NIH, S3 Capital	58/100
4th	Beyond Air 2011, Garden City (United States), Public	Developer of therapeutics for multiple diseases	-	Collage Venture Partners, Cystic Fibrosis Foundation ... Read more	57/100
5th	Alexza 2000, Mountain View (United States), Public	Developer of products for the treatment of acute and intermittent conditions	$97M	Versant Ventures, Frazier Healthcare Partners ... & 16 others	56/100
6th	Iconovo 2013, Lund (Sweden), Public	Develops inhalation devices	$3.56M	Smile Incubator, Eiffel Investment Group & 2 others	55/100
7th	Qnovia 2018, Richmond (United States), Series B	Developer of inhaled drug delivery devices to deliver a broad range of pharmaceuticals	$50M	Blue Ledge Capital, Evolution VC Partners ... & 4 others	54/100
8th	OptiNose 2000, Morrisville (United States), Acquired	Developer of smart devices for nasal drug delivery	$120M	Avista Capital Partners, Fidelity Investments ... & 6 others	53/100
9th	Aerogen 1997, Galway (Ireland), Acquired	Manufacturer of vibrating mesh nebulizers for aerosol drug delivery	$18M	Western Technology Investment, Invesco Mutual Fund ... & 10 others	52/100
10th	Nebu~Flow 2019, Glasgow (United Kingdom), Series A	Developer of aerosol delivery platform technology	$7.97M	Foresight Group, SCVC & 8 others	51/100
40th	HCmed 2014, Taipei (Taiwan), Public	Developer of inhalation device to treat people suffering from respiratory diseases.	-	-	27/100